Ovarian Cancer Real-World Data Identify Significant Differences in Tolerability Among Approved PARP Inhibitors in Ovarian CancerBy adminJune 14, 20220 Patients with ovarian cancer treated with FDA-approved PARP inhibitors had significant differences in the incidence of clinically relevant adverse events…
